Joyce O’Shaughnessy, MD
Professor and Co-Chair of Breast Cancer Research
Chair of Breast Cancer Prevention Research
Baylor-Sammons Cancer Center and US Oncology
Texas Oncology P.A.
Charles A Sammons Cancer Center
Physician CME 1 hour
Nursing CE 1 hour Medium
This online program was originally presented as a live audioconference throughout October and November of 2006. If you received credit from the audioconference, you are not eligible to apply for credit through this online version.
Breast cancer outcomes in the United States are improving, with decreased mortality despite rising incidence. This improvement is attributable to both earlier detection and diagnosis as well as advances in treatment. However, Stage IV, or metastatic breast cancer (MBC), remains largely incurable. If MBC occurs, there is a 16%-20% estimated 5-year survival rate. Treatment for MBC is focused on extending survival time and relieving symptoms.
This educational program will focus on ways to continue improving patient outcomes in MBC by reviewing options to evaluate the success of MBC treatment strategies and discussing ways to successfully manage a side effect of the cancer and treatment itself: anemia. The discussion will center on recently completed and ongoing trials addressing the role of therapy, along with circulating tumor cells and novel biomarkers in patients with MBC and the incidence and management of anemia.
. Target Audience
Oncologists, oncology nurses, pathologists, and other clinicians who care for women with metastatic breast cancer
Upon completion of this educational activity, the participant should be able to:
List current treatment strategies for metastatic breast cancer.
Outline methods for evaluating tumor response to metastatic breast cancer therapy.
Discuss the NCCN and ASH/ASCO guidelines for treatment of symptomatic anemia in the cancer patient to include disease-induced and treatment-induced.
Review practical aspects of implementation of anemia treatment options.
It is the policy of AKH Inc. to ensure independence, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Dr. O’Shaughnessy discloses that she has no actual or potential conflict of interest to this program or presentation.
This educational activity may contain discussion of published and/or investigational uses of oncology agents. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity. ™
Nurses: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
AKH Inc. designates this educational activity for 1.0 contact hour (0.1 CEU).
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit. There is no fee to participate and receive credit.
Commercial Support Statements
Supported by educational grants from ORTHO BIOTECH and VERIDEX.
Please turn off all pop-up blockers and click on the "Start Program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program. Clicking on the "slides" button on this screen will begin the program presentation. Clicking on the "Q and A" button will bring you to the pre-recording question-and-answer session. The program, Q and A, post-test, and evaluation will take approximately 60 minutes to complete.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CE certificate.
None of the contents may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this publication and audioconference are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., Ortho Biotech, or Veridex. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.